|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
gptkb:reversible_inhibitor_of_monoamine_oxidase_A
|
|
gptkbp:approvedBy
|
gptkb:Australia
gptkb:Canada
gptkb:Europe
1989
|
|
gptkbp:ATCCode
|
N06AG02
|
|
gptkbp:brand
|
gptkb:Aurorix
gptkb:Manerix
gptkb:Amira
|
|
gptkbp:CASNumber
|
71320-77-9
|
|
gptkbp:compatibleWith
|
gptkb:United_States
|
|
gptkbp:contraindication
|
gptkb:pheochromocytoma
severe liver impairment
|
|
gptkbp:developedBy
|
gptkb:Hoffmann-La_Roche
|
|
gptkbp:drugClass
|
gptkb:monoamine_oxidase_inhibitor
|
|
gptkbp:eliminationHalfLife
|
2 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C13H17ClN2O2
|
|
gptkbp:interactsWith
|
gptkb:tricyclic_antidepressants
gptkb:dextromethorphan
gptkb:SSRIs
gptkb:meperidine
tyramine-containing foods
|
|
gptkbp:IUPACName
|
4-chloro-N-(2-morpholin-4-ylethyl)benzamide
|
|
gptkbp:KEGGID
|
D08210
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
reversible inhibition of monoamine oxidase A
|
|
gptkbp:meltingPoint
|
108-110°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
B3 (Australia)
|
|
gptkbp:proteinBinding
|
50%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL137
4185
4041
DB01171
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
headache
insomnia
dry mouth
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:UNII
|
7R4A8J977N
|
|
gptkbp:usedFor
|
treatment of depression
treatment of social anxiety disorder
|
|
gptkbp:bfsParent
|
gptkb:N06AX
gptkb:MAO-A
gptkb:Aurorix
gptkb:Manerix
gptkb:monoamine_oxidase_A
gptkb:CYP2C19_gene
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
moclobemide
|